TELA Bio, Inc., a surgical reconstruction company, was created out of the desire to do things differently. Combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. Based in Malvern, Pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients.
Please see our social media community guidelines at http://bit.ly/1UVcx0L
Please see our social media community guidelines at http://bit.ly/1UVcx0L
Location: United States, Pennsylvania, Malvern
Employees: 51-200
Phone: +1 484-320-2930
Total raised: $71.3M
Founded date: 2012
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 26.03.2018 | - | $1M | - |
| 30.10.2017 | - | $25M | - |
| - | - | $45.3M | - |
Mentions in press and media 16
| Date | Title | Description |
| 07.09.2026 | Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction | Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 7, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (... |
| 28.08.2025 | FIRST CLINICAL EVIDENCE PUBLISHED ON AROA's ENIVO™ SYSTEM FOR SURGICAL DEAD SPACE MANAGEMENT. | AUCKLAND, New Zealand, Aug. 27, 2025 /PRNewswire/ -- AROA is pleased to announce the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospect... |
| 31.05.2022 | TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial | MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outco... |
| 04.10.2021 | EW Healthcare Partners Announces the Promotion of Senior Executives | Oct 04 2021 NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the promotion of senior executives of their investment team. • Brooks Andrews has bee... |
| 03.09.2021 | Recent Developments in Soft Tissue Reconstruction to be Explored on an Upcoming Episode of Advancements | JUPITER, Fla. (PRWEB) September 03, 2021 Scheduled to broadcast 4Q/2021, Advancements with Ted Danson will focus on breakthroughs in soft tissue repair solutions. Check local listings for more information. Hearing from experts in the field,... |
| 13.12.2019 | TELA Bio Announces Closing of Initial Public Offering of Common Stock | Dec 13 2019 MALVERN, Pennsylvania—TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs ... |
| 06.12.2019 | TELA Bio Awarded Contract with HealthTrust Purchasing Group | Dec 06 2019 MALVERN, Pennsylvania—TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs ... |
| 11.12.2018 | Tela Bio raises more than $2 million | Regenerative surgical implants company Tela Bio has brought in more than $2 million in investments, according to a recent U.S. Securities and Exchange Commission filing. The Malvern, Pa.–based company had sought to raise a total $3 million,... |
| 16.04.2018 | TELA Bio Announces Series B Investment by Checkmate Capital | TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that Checkmate Capital, a strategic investment group based in... |
| 26.03.2018 | Tela Bio Receives $1M in Funding | Tela Bio, Inc., a Malvern, Pa.-based surgical reconstruction company focused on development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, received $1m in funding. ProMedica, a mission-based, not-for... |
Show more